Clinical Trial Update: 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)

View source ↗

Summary

A post-marketing surveillance trial of olaparib (Lynparza) conducted by AstraZeneca has completed, reporting safety monitoring results across ovarian cancer, br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian Cancer, Breast Cancer | Status: COMPLETED